TABLE 1.
Demographic and Clinical Characteristics of 138 Patients with Adult Rhabdomyosarcoma
| Descriptor | No. | % |
|---|---|---|
| Gender | ||
| Female | 60 | 43 |
| Male | 78 | 57 |
| Age | ||
| <21 | 41 | 30 |
| 21–40 | 61 | 44 |
| >40 | 36 | 26 |
| KPS | ||
| >70% | 90 | 77 |
| 27 | 23 | |
| ≤70 | 15 | 11 |
| Primary site | 29 | 21 |
| Orbit | 24 | 17 |
| Head and neck | 6 | 4 |
| GU non-BP | 30 | 22 |
| Parameningeal | 34 | 25 |
| GU BP | ||
| Extremity | ||
| Other | ||
| Histology | ||
| Embryonal | 74 | 54 |
| Alveolar | 45 | 33 |
| Pleomorphic | 16 | 12 |
| NOS | 3 | 2 |
| IRS Group | ||
| I | 20 | 14 |
| II | 25 | 18 |
| III | 49 | 36 |
| IV | 44 | 32 |
| COG risk group | ||
| Low-risk | 33 | 24 |
| Intermediate-risk | 61 | 44 |
| High-risk | 44 | 32 |
| Treatment | ||
| Chemotherapy | 125 | 91 |
| Surgery | 90 | 65 |
| Radiation (any) | 101 | 73 |
| Radiation to primary site | 90 | 65 |
| Chemotherapy | ||
| None | 13 | 9 |
| VAC | 33 | 24 |
| VADRC | 72 | 52 |
| Ifos/ADR | 5 | 4 |
| MAID | 4 | 3 |
| Unknown | 2 | 1 |
| Other | 9 | 7 |
| On or according to protocol | 64 | 46 |
Abbreviations: GU BP, genitourinary bladder/prostate; GU non-BP, genitourinary non-bladder/prostate; NOS, not otherwise specified; IRS, Intergroup Rhabdomyosarcoma Study; COG, Children’s Oncology Group; VAC, vincristine, dactinomycin, cyclophosphamide; VADRC, vincristine, doxorubicin, cyclophosphamide; Ifos, ifosfamide; ADR, doxorubicin; MAID, mesna, doxorubicin, ifosfamide, and dacarbazine.